VCYT News and Press, Veracyte Inc. From 05/24/23

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoraci...

2023-05-22 07:30:00 ET Buying growth stocks on the cheap can be a great way to build wealth for investors with enough patience. This is because the strategy combines the high return potential of growth investing with the downside protection that comes with value investing. Diagnostic co...

2023-05-16 02:33:22 ET Summary With its range of products, Veracyte displays a robust and diverse portfolio, targeting multiple areas in oncology. Veracyte's recent data underscores the company's innovative edge in the field of genomic diagnostics, specifically with the Decipher P...

Findings from prospective, population-based study presented at ESMO Breast Cancer Congress 2023 Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including s...

2023-05-04 22:43:09 ET Veracyte, Inc. (VCYT) Q1 2023 Earnings Conference Call May 04, 2023 04:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conf...

2023-05-04 16:46:35 ET Veracyte press release ( NASDAQ: VCYT ): Q1 GAAP EPS of -$0.11 beats by $0.03 . Revenue of $82.42M (+21.6% Y/Y) beats by $6.67M . Testing revenue was $72.4 million, an increase of 29% compared to $56.0 million in the first quarter of 2022...

Grew Total Revenue to $82.4 million, an Increase of 22% Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2023. “We had an excellent first quarter, as many areas ...

Findings reinforce value of Veracyte’s expanded Afirma offering, which now includes TERT gene mutation testing Veracyte, Inc . (Nasdaq: VCYT) announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodul...

Veracyte, Inc . (Nasdaq: VCYT) announced that data published in the journal Cancer show the ability of a novel gene expression signature to classify prostate cancer into distinct molecular subtypes that may inform which tumors are more likely to respond to different treatments. The find...

2023-05-03 17:35:59 ET Veracyte ( NASDAQ: VCYT ) is scheduled to announce Q1 earnings results on Thursday, May 4th, after market close. The consensus EPS Estimate is -$0.11 (+45.0% Y/Y) and the consensus Revenue Estimate is $75.75M (+11.8% Y/Y). Over the last 1 year, V...